As of August 30, 2026. The U.S. Department of Commerce has issued final antidumping-duty (AD) and countervailing-duty (CVD) determinations concerning van-type trailers from the People's Republic of China. The determinations are commercially significant for importers, purchasers, manufacturers, distributors, customs brokers, and lenders that rely on Chinese-origin trailer supply chains.

Commerce's final determinations establish final AD and CVD cash-deposit rates for covered Chinese van-type trailers. The applicable rate depends on the producer, exporter, and whether the merchandise falls within the China-wide entity. The China-wide AD and CVD rates are particularly important because a shipment that cannot be tied to a separate, qualifying producer/exporter may be entered at those rates.

A final Commerce determination does not by itself complete the trade-remedy process. The U.S. International Trade Commission (ITC) must make a final affirmative injury determination before AD/CVD orders are issued. If the ITC reaches an affirmative determination, CBP will collect cash deposits under the final rates and the orders will govern future covered entries. If the ITC reaches a negative determination, the investigation will terminate and the provisional measures framework will be addressed under the governing process.

Importers should therefore treat this update as an immediate compliance and contracting issue, while preserving the distinction between Commerce's final determinations and the ITC's separate injury decision.

“Van-type trailer” is a trade-remedy scope concept, not simply a commercial product label or a broad customs category. Coverage turns on the written scope of the investigations and the product's physical characteristics, configuration, components, and country of origin. An HTSUS classification is relevant to entry administration, but it does not replace a scope analysis.

Companies should build a product-level record for every potentially affected trailer, including:

• purchase order and commercial description;
• technical specifications, drawings, dimensions, and photographs;
• chassis, body, axle, suspension, and assembly information;
• producer and exporter identity;
• manufacturing and substantial-transformation steps; and
• HTSUS classification, country-of-origin declarations, and prior CBP entry data.

This mapping helps a company determine whether a product is covered, identify the correct exporter/producer combination for cash-deposit purposes, and respond efficiently to broker, customer, lender, or government inquiries.

The final determinations also make Canadian routing a key operational point. Moving merchandise through Canada, including by warehousing, transshipment, or a Canadian distribution arrangement, does not by itself change Chinese origin. For ACE entry purposes, importers must ensure that country-of-origin, manufacturer, exporter, and entry information accurately reflects the underlying product and supply chain.

A Canadian transaction may involve separate customs, origin, valuation, and transportation considerations. It should not, however, be used as a substitute for a documented origin analysis. If processing in Canada is claimed to change origin, the importer needs a fact-specific substantial-transformation analysis supported by manufacturing records. A paper change in seller, invoice flow, or shipping route is not enough.

The timing of an AD/CVD order, the possibility of later administrative reviews, and the distinction between estimated deposits and final liability create material commercial risk. Import contracts should not rely solely on an all-in unit price when AD/CVD exposure is possible.

Commercial teams should review whether agreements address:

1. responsibility for AD/CVD cash deposits, duties, interest, penalties, and broker costs;
2. price adjustments if a product is found covered or if a rate changes;
3. supplier representations on producer, exporter, origin, and manufacturing facts;
4. audit rights and access to records supporting origin and scope analysis;
5. indemnification, reimbursement timing, and security for duty exposure;
6. notice obligations for government inquiries, scope rulings, and changes in supply chain; and
7. termination, substitution, delay, and force-majeure provisions when compliance prevents delivery.

Importers should also align supplier representations with the documentation that will actually accompany the entry. A representation is less useful if invoices, packing lists, bills of materials, or factory records point to a different producer or origin story.

First, identify open purchase orders, goods in production, goods in transit, bonded inventory, and future sourcing commitments involving potentially covered trailers. Second, confirm each transaction's producer, exporter, route, and origin documentation with customs counsel and the broker before entry. Third, model the final cash-deposit rates and a conservative downside scenario into landed-cost, financing, and customer-pricing decisions.

Finally, monitor the ITC's final injury determination and any subsequent order instructions. Trade-remedy exposure is highly fact-specific. A timely scope, origin, and contract review is generally less costly than correcting entry data after goods are imported.

This publication is for general informational purposes only and does not constitute legal advice. AD/CVD scope, rates, origin, classification, entry treatment, and contract rights depend on the specific merchandise, parties, documents, and timing involved.